Cargando…

人非小细胞肺癌NCI-H1299细胞特异性结合肽的筛选及鉴定

BACKGROUND AND OBJECTIVE: Non-small cell lung cancer (NSCLC) is the most common histological type of lung cancer, and one of the malignant tumor with the highest mortality. As the main part of the optical molecular imaging probe, peptide can realize the early screening and diagnosis of tumor and imp...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786229/
https://www.ncbi.nlm.nih.gov/pubmed/33357309
http://dx.doi.org/10.3779/j.issn.1009-3419.2020.103.17
_version_ 1783632583428407296
collection PubMed
description BACKGROUND AND OBJECTIVE: Non-small cell lung cancer (NSCLC) is the most common histological type of lung cancer, and one of the malignant tumor with the highest mortality. As the main part of the optical molecular imaging probe, peptide can realize the early screening and diagnosis of tumor and improve the survival rate of patients. The aim of this study was to screen the small-molecule peptide that highly binds to NSCLC NCI-H1299 cells using in vivo phage display technology and to identify their binding specificity by in vitro experiment. METHODS: To prepare a tumor-bearing nude mouse model of NCI-H1299 cells, after 3 rounds of in vivo screening with Ph.D.-C7CTM Peptide Library, phage clones were randomly picked, using immunohistochemistry and enzyme-linked immunosorbent assay (ELISA) to identify the affinity of phage clones to NCI-H1299 cells. The positive monoclonal phages DNA was extracted and sequenced to obtain the amino acid sequence of the peptides. The peptides with the highest repetition rate was chemically synthesized and labeled with fluorescein (FITC) to prepare optical molecular probe. We preliminary identified the specificity of the probe binding to lung cancer cells by in vitro experiment. RESULTS: After three rounds of in vivo screening, the phages enrichment rate was 341.3 times compared with the first round. Immunohistochemical staining showed that with the increase of screening times, the phages binding to tumor tissues continued to increase, and the binding amount was significantly higher than normal tissues; ELISA results showed that 20 clones among the 30 randomly selected phage clones were positive. After sequencing, the peptide with the highest repetition rate was synthesized and named NSP1; Methyl thiazolyl tetrazolium assay (MTT) and would healing assay showed that NSP1 will not affect cell proliferation and migration. Flow cytometry and immunofluorescence showed specific binding of NSP1 to NCI-H1299 cells. CONCLUSION: We successfully obtained the peptide NSP1 that specifically binds to lung cancer NCI-H1299 cells by in vivo phage display, which provide a theoretical basis for NSCLC early diagnosis and targeted therapy.
format Online
Article
Text
id pubmed-7786229
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-77862292021-01-14 人非小细胞肺癌NCI-H1299细胞特异性结合肽的筛选及鉴定 Zhongguo Fei Ai Za Zhi 基础研究 BACKGROUND AND OBJECTIVE: Non-small cell lung cancer (NSCLC) is the most common histological type of lung cancer, and one of the malignant tumor with the highest mortality. As the main part of the optical molecular imaging probe, peptide can realize the early screening and diagnosis of tumor and improve the survival rate of patients. The aim of this study was to screen the small-molecule peptide that highly binds to NSCLC NCI-H1299 cells using in vivo phage display technology and to identify their binding specificity by in vitro experiment. METHODS: To prepare a tumor-bearing nude mouse model of NCI-H1299 cells, after 3 rounds of in vivo screening with Ph.D.-C7CTM Peptide Library, phage clones were randomly picked, using immunohistochemistry and enzyme-linked immunosorbent assay (ELISA) to identify the affinity of phage clones to NCI-H1299 cells. The positive monoclonal phages DNA was extracted and sequenced to obtain the amino acid sequence of the peptides. The peptides with the highest repetition rate was chemically synthesized and labeled with fluorescein (FITC) to prepare optical molecular probe. We preliminary identified the specificity of the probe binding to lung cancer cells by in vitro experiment. RESULTS: After three rounds of in vivo screening, the phages enrichment rate was 341.3 times compared with the first round. Immunohistochemical staining showed that with the increase of screening times, the phages binding to tumor tissues continued to increase, and the binding amount was significantly higher than normal tissues; ELISA results showed that 20 clones among the 30 randomly selected phage clones were positive. After sequencing, the peptide with the highest repetition rate was synthesized and named NSP1; Methyl thiazolyl tetrazolium assay (MTT) and would healing assay showed that NSP1 will not affect cell proliferation and migration. Flow cytometry and immunofluorescence showed specific binding of NSP1 to NCI-H1299 cells. CONCLUSION: We successfully obtained the peptide NSP1 that specifically binds to lung cancer NCI-H1299 cells by in vivo phage display, which provide a theoretical basis for NSCLC early diagnosis and targeted therapy. 中国肺癌杂志编辑部 2020-12-20 /pmc/articles/PMC7786229/ /pubmed/33357309 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.103.17 Text en 版权所有©《中国肺癌杂志》编辑部2020 This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 基础研究
人非小细胞肺癌NCI-H1299细胞特异性结合肽的筛选及鉴定
title 人非小细胞肺癌NCI-H1299细胞特异性结合肽的筛选及鉴定
title_full 人非小细胞肺癌NCI-H1299细胞特异性结合肽的筛选及鉴定
title_fullStr 人非小细胞肺癌NCI-H1299细胞特异性结合肽的筛选及鉴定
title_full_unstemmed 人非小细胞肺癌NCI-H1299细胞特异性结合肽的筛选及鉴定
title_short 人非小细胞肺癌NCI-H1299细胞特异性结合肽的筛选及鉴定
title_sort 人非小细胞肺癌nci-h1299细胞特异性结合肽的筛选及鉴定
topic 基础研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786229/
https://www.ncbi.nlm.nih.gov/pubmed/33357309
http://dx.doi.org/10.3779/j.issn.1009-3419.2020.103.17
work_keys_str_mv AT rénfēixiǎoxìbāofèiáincih1299xìbāotèyìxìngjiéhétàideshāixuǎnjíjiàndìng
AT rénfēixiǎoxìbāofèiáincih1299xìbāotèyìxìngjiéhétàideshāixuǎnjíjiàndìng
AT rénfēixiǎoxìbāofèiáincih1299xìbāotèyìxìngjiéhétàideshāixuǎnjíjiàndìng
AT rénfēixiǎoxìbāofèiáincih1299xìbāotèyìxìngjiéhétàideshāixuǎnjíjiàndìng
AT rénfēixiǎoxìbāofèiáincih1299xìbāotèyìxìngjiéhétàideshāixuǎnjíjiàndìng